[go: up one dir, main page]

SI2578585T1 - Purinonski derivat kot BTK kinazni inhibitor - Google Patents

Purinonski derivat kot BTK kinazni inhibitor

Info

Publication number
SI2578585T1
SI2578585T1 SI201130923A SI201130923A SI2578585T1 SI 2578585 T1 SI2578585 T1 SI 2578585T1 SI 201130923 A SI201130923 A SI 201130923A SI 201130923 A SI201130923 A SI 201130923A SI 2578585 T1 SI2578585 T1 SI 2578585T1
Authority
SI
Slovenia
Prior art keywords
kinase inhibitor
btk kinase
purinone derivative
purinone
derivative
Prior art date
Application number
SI201130923A
Other languages
English (en)
Inventor
Shingo Yamamoto
Toshio Yoshizawa
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Publication of SI2578585T1 publication Critical patent/SI2578585T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201130923A 2010-05-31 2011-05-30 Purinonski derivat kot BTK kinazni inhibitor SI2578585T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010123727 2010-05-31
PCT/JP2011/062377 WO2011152351A1 (ja) 2010-05-31 2011-05-30 プリノン誘導体
EP11789754.6A EP2578585B1 (en) 2010-05-31 2011-05-30 Purinone derivative as btk kinase inhibitor

Publications (1)

Publication Number Publication Date
SI2578585T1 true SI2578585T1 (sl) 2016-10-28

Family

ID=45066718

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130923A SI2578585T1 (sl) 2010-05-31 2011-05-30 Purinonski derivat kot BTK kinazni inhibitor

Country Status (28)

Country Link
US (10) US8940725B2 (sl)
EP (3) EP2578585B1 (sl)
JP (3) JP5648686B2 (sl)
KR (1) KR101537148B1 (sl)
CN (1) CN102918040B (sl)
AU (1) AU2011260961B9 (sl)
BR (2) BR112012030711B1 (sl)
CA (1) CA2800523C (sl)
CY (1) CY1118088T1 (sl)
DK (1) DK2578585T3 (sl)
ES (3) ES2782873T3 (sl)
HR (1) HRP20161027T1 (sl)
HU (1) HUE030720T2 (sl)
IL (1) IL223361A (sl)
LT (1) LT2578585T (sl)
MX (1) MX2012013622A (sl)
MY (2) MY169745A (sl)
NZ (1) NZ603643A (sl)
PH (1) PH12012502369A1 (sl)
PL (1) PL2578585T3 (sl)
PT (1) PT2578585T (sl)
RS (1) RS55184B1 (sl)
SG (2) SG10201503991SA (sl)
SI (1) SI2578585T1 (sl)
SM (1) SMT201600360B (sl)
TW (2) TWI500617B (sl)
WO (1) WO2011152351A1 (sl)
ZA (1) ZA201208900B (sl)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
US8962831B2 (en) 2011-05-17 2015-02-24 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
ES2950569T3 (es) 2011-07-19 2023-10-11 Merck Sharp & Dohme (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk
BR112014012727B1 (pt) * 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
NZ713828A (en) 2012-06-04 2017-05-26 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
WO2014025976A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
RS58956B1 (sr) 2012-09-10 2019-08-30 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
CA2890934A1 (en) 2012-11-15 2014-05-22 Pharmacyclics, Inc. Pyrrolopyrimidine compounds as kinase inhibitors
US8895750B2 (en) 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
WO2014152114A1 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
AU2014256633B2 (en) 2013-04-25 2017-02-02 Beone Medicines I Gmbh Fused heterocyclic compounds as protein kinase inhibitors
US9637487B2 (en) 2013-07-02 2017-05-02 Pharmacyclics Llc Purinone compounds as kinase inhibitors
WO2015035606A1 (en) 2013-09-13 2015-03-19 Beigene, Ltd. Anti-pd1 antibodies and their use as therapeutics and diagnostics
PE20160560A1 (es) 2013-09-30 2016-06-09 Pharmacyclics Llc DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK)
CN114632158A (zh) * 2013-11-07 2022-06-17 豪夫迈·罗氏有限公司 抗cd20抗体与btk抑制剂的组合疗法
BR112016012794A2 (pt) 2013-12-05 2017-08-08 Acerta Pharma Bv Combinação terapêutica de um inibidor de pi3k e um inibidor de btk
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015116485A1 (en) 2014-01-29 2015-08-06 Boehringer Ingelheim International Gmbh Pyrazole compounds as btk inhibitors
MX372673B (es) 2014-02-21 2020-03-25 Principia Biopharma Inc Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
MX2016011674A (es) 2014-03-12 2017-04-27 Novartis Ag Combinacion que comprende un inhibidor de btk y un inhibidor de akt.
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
EP3122360B1 (en) 2014-03-25 2020-06-17 ONO Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
TWI681954B (zh) 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN106573922A (zh) 2014-06-13 2017-04-19 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
US9949971B2 (en) 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
RU2017106795A (ru) 2014-08-07 2018-09-07 Фармасайкликс Элэлси Новые составы ингибитора тирозинкиназы брутона
RS62713B1 (sr) 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
ES2843323T3 (es) 2014-12-18 2021-07-16 Principia Biopharma Inc Tratamiento de pénfigo
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
WO2016141092A1 (en) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
ES2955554T3 (es) 2015-04-09 2023-12-04 Ono Pharmaceutical Co Proceso para producir un derivado de purinona
TWI810582B (zh) * 2015-06-03 2023-08-01 美商普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
EP3313405A1 (en) * 2015-06-23 2018-05-02 Gilead Sciences, Inc. Combination therapies for treating b-cell malignancies
EP3313839A1 (en) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP6829215B2 (ja) 2015-07-02 2021-02-10 アセルタ ファーマ ビー．ブイ． （Ｓ）−４−（８−アミノ−３−（１−（ブト−２−イノイル）ピロリジン−２−イル）イミダゾ［１，５−ａ］ピラジン−１−イル）−Ｎ−（ピリジン−２−イル）ベンザミドの固体形態及び製剤
WO2017035230A1 (en) 2015-08-26 2017-03-02 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
JP2018530550A (ja) 2015-10-01 2018-10-18 ギリアド サイエンシズ， インコーポレイテッド 癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ
US10358446B2 (en) 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
ES2897910T3 (es) 2015-12-16 2022-03-03 Boehringer Ingelheim Int Derivados bipirazolilo útiles para el tratamiento de enfermedades autoinmunitarias
WO2017123695A1 (en) 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
CA3019003A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
SI3458053T1 (sl) 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Uporaba riluzola, predzdravil riluzola ali analogov riluzola z imunoterapijami za zdravljenje rakov
SG11201809893WA (en) 2016-05-27 2018-12-28 Gilead Sciences Inc Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
US20190231784A1 (en) 2016-06-29 2019-08-01 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
JP6993056B2 (ja) 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
EP4353322A3 (en) 2016-08-16 2024-07-31 BeiGene Switzerland GmbH Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN107759602B (zh) * 2016-08-17 2020-04-21 中国科学院上海药物研究所 含有共轭联烯结构的化合物、其药物组合物和用途
CN109851620B (zh) * 2016-08-17 2020-08-07 深圳市塔吉瑞生物医药有限公司 用于抑制酪氨酸激酶活性的稠合双环类化合物
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3507276B1 (en) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP4230627A3 (en) * 2016-09-16 2023-11-15 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
CN117402852A (zh) 2016-10-14 2024-01-16 精密生物科学公司 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
EP3560926B1 (en) * 2016-12-21 2022-02-23 Ono Pharmaceutical Co., Ltd. 6-amino-7,9-dihydro-8h-purin-8-one compounds as brk inhibitors
CN106588937B (zh) 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
TWI774726B (zh) 2017-01-25 2022-08-21 英屬開曼群島商百濟神州有限公司 (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
TWI820984B (zh) 2017-01-31 2023-11-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
AR110998A1 (es) * 2017-02-24 2019-05-22 Gilead Sciences Inc Inhibidores de la tirosina cinasa de bruton
JP2020508326A (ja) * 2017-02-24 2020-03-19 ギリアド サイエンシズ， インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN109111446B (zh) * 2017-06-22 2021-11-30 上海度德医药科技有限公司 一种具有药物活性的杂芳基化合物
TWI877099B (zh) 2017-06-26 2025-03-21 英屬開曼群島商百濟神州有限公司 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
WO2019040102A1 (en) 2017-08-22 2019-02-28 Gilead Sciences, Inc. THERAPEUTIC HETEROCYCLIC COMPOUNDS
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CA3087886A1 (en) * 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
KR102586510B1 (ko) 2018-02-13 2023-10-12 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
AU2019255750B2 (en) 2018-04-19 2021-10-21 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP3789040A4 (en) 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
AU2019297362B2 (en) 2018-07-06 2022-05-26 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
CA3104398A1 (en) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020043321A1 (en) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
SG11202103839UA (en) 2018-10-31 2021-05-28 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CA3129022C (en) 2019-03-07 2023-08-01 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
TW202446397A (zh) 2019-06-10 2024-12-01 瑞士商百濟神州瑞士有限責任公司 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
KR20220080179A (ko) 2019-10-14 2022-06-14 프린시피아 바이오파마, 인코퍼레이티드 (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을 투여하여 면역 혈소판 감소증을 치료하는 방법
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
TWI875911B (zh) 2020-01-02 2025-03-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｂｒｕｔｏｎ酪胺酸激酶（ＢＴＫ）抑制劑
IL294560A (en) 2020-01-20 2022-09-01 Genzyme Corp Medicinal tyrosine kinase inhibitors for relapsing multiple sclerosis
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202140484A (zh) 2020-01-22 2021-11-01 美商普林斯匹亞生物製藥公司 ２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）－１Ｈ－吡唑并［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈之晶形
KR20220156884A (ko) 2020-03-20 2022-11-28 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022087422A1 (en) 2020-10-22 2022-04-28 Chulalongkorn University Pyrrolidine-3-carboxamide derivatives and related uses
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3201936A1 (en) 2020-12-10 2022-06-16 Minhua Chen Crystal form of tolebrutinib and preparation method thereof
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022242740A1 (zh) * 2021-05-21 2022-11-24 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
JP7654118B2 (ja) 2021-06-23 2025-03-31 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023155760A1 (zh) * 2022-02-16 2023-08-24 贝达药业股份有限公司 一种药物组合物及所含活性成分化合物的制备方法
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
EP4573097A1 (en) * 2022-08-16 2025-06-25 Beijing Neox Biotech Limited Btk degrading compounds
WO2024104277A1 (zh) * 2022-11-14 2024-05-23 天津征程医药科技有限公司 作为btk抑制剂的嘌呤衍生物
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
CN118598781B (zh) * 2024-06-13 2025-06-10 迪嘉药业集团股份有限公司 一种孟鲁司特钠关键中间体的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509427A (ja) * 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療剤としてのキナーゼ阻害剤
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
BRPI0413005A (pt) * 2003-07-29 2006-09-26 Irm Llc compostos e composições como inibidores da proteìna cinase
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2008060301A1 (en) 2006-11-16 2008-05-22 Pharmacopeia , Llc 7-substituted purine derivatives for immunosuppression
EP2954900A1 (en) * 2007-03-28 2015-12-16 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20080244408A1 (en) 2007-03-30 2008-10-02 Jimmy Dugan King Internet Search Engine with Display
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
EP2771010A4 (en) 2011-10-19 2015-04-01 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
TW201427667A (zh) 2012-11-20 2014-07-16 Celgene Avilomics Res Inc 治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
CN114632158A (zh) 2013-11-07 2022-06-17 豪夫迈·罗氏有限公司 抗cd20抗体与btk抑制剂的组合疗法
RS62713B1 (sr) 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora

Also Published As

Publication number Publication date
KR20130109941A (ko) 2013-10-08
HRP20161027T1 (hr) 2016-11-04
CN102918040A (zh) 2013-02-06
TW201209057A (en) 2012-03-01
JP5648686B2 (ja) 2015-01-07
EP2578585A4 (en) 2013-10-23
PH12012502369A1 (en) 2013-02-11
US20200048256A1 (en) 2020-02-13
US20130079327A1 (en) 2013-03-28
MY189483A (en) 2022-02-16
EP3590938A1 (en) 2020-01-08
JP2016185954A (ja) 2016-10-27
TW201533046A (zh) 2015-09-01
US20240083899A1 (en) 2024-03-14
CN102918040B (zh) 2015-03-18
KR101537148B1 (ko) 2015-07-15
EP3112368A1 (en) 2017-01-04
AU2011260961B9 (en) 2015-02-26
TWI500617B (zh) 2015-09-21
NZ603643A (en) 2014-07-25
SMT201600360B (it) 2016-11-10
US9879013B2 (en) 2018-01-30
ZA201208900B (en) 2013-09-25
MY169745A (en) 2019-05-14
US10233185B2 (en) 2019-03-19
BR112012030711B1 (pt) 2020-10-13
WO2011152351A1 (ja) 2011-12-08
PT2578585T (pt) 2016-09-23
ES2782873T3 (es) 2020-09-16
US20250197401A1 (en) 2025-06-19
AU2011260961B2 (en) 2015-02-05
EP2578585B1 (en) 2016-07-20
US20130217880A1 (en) 2013-08-22
JP2015052000A (ja) 2015-03-19
LT2578585T (lt) 2016-10-10
EP3590938B1 (en) 2023-05-24
US9926322B2 (en) 2018-03-27
SG185617A1 (en) 2012-12-28
ES2592152T3 (es) 2016-11-28
EP3112368B1 (en) 2020-02-12
US20180170933A1 (en) 2018-06-21
SG10201503991SA (en) 2015-07-30
JP6176353B2 (ja) 2017-08-09
CY1118088T1 (el) 2017-06-28
CA2800523A1 (en) 2011-12-08
US20190169192A1 (en) 2019-06-06
JPWO2011152351A1 (ja) 2013-08-01
US20170313705A1 (en) 2017-11-02
MX2012013622A (es) 2013-02-01
HK1178882A1 (en) 2013-09-19
BR112012030711A2 (pt) 2016-11-01
US8940725B2 (en) 2015-01-27
BR122018011748B1 (pt) 2021-12-07
RU2012157072A (ru) 2014-07-20
US20220363684A1 (en) 2022-11-17
IL223361A (en) 2015-11-30
DK2578585T3 (en) 2016-11-14
ES2948312T3 (es) 2023-09-08
TWI535716B (zh) 2016-06-01
RS55184B1 (sr) 2017-01-31
AU2011260961A1 (en) 2013-01-10
HUE030720T2 (en) 2017-06-28
CA2800523C (en) 2018-09-18
US8557803B2 (en) 2013-10-15
US10487085B2 (en) 2019-11-26
JP5924393B2 (ja) 2016-05-25
US20150094299A1 (en) 2015-04-02
PL2578585T3 (pl) 2017-01-31
EP2578585A1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
PL2578585T3 (pl) Pochodna purynonu jako inhibitor kinazy btk
IL261282A (en) Furinone compounds as kinase inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
ZA201404792B (en) Purinone derivative hydrochloride
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
HUE048834T2 (hu) Kináz inhibitorok
IL228103A0 (en) Amino-quinolines as kinase inhibitors
ZA201404156B (en) Kinase inhibitors
ZA201401211B (en) Kinase inhibitor polymorphs
IL229028A0 (en) Kinase inhibitors
SG11201501173SA (en) PI3Kδ INHIBITOR
GB201009731D0 (en) Kinase inhibitors
EP2776428A4 (en) KINASEHEMMERPOLYMORPHE
EP2895167A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
ZA201404157B (en) Kinase inhibitors
ZA201405505B (en) Novel imidazopyridine derivatives as a tyrosine kinase inhibitor
GB201009730D0 (en) Kinase inhibitor compounds